PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I): wherein: V and U are hydrogen, halogen, C1-C4 alkylamino, or together form a group that contains one or more heteroatoms, and that taken together with one or more: (a) hydrogen atoms; (b) carbon atoms; (c) -CH- groups; (d) -CH2- groups; or...

Full description

Saved in:
Bibliographic Details
Main Authors BIELIK ATTILA, HORVÁTH CSILLA, BARTÁNÉ SZALAI GIZELLA, KESERÜ GYÖRGY, KOLOK SÁNDOR, NAGY JÓZSEF, VÁGÓ ISTVÁN, IGNÁCZNÉ SZENDREI GYÖRGYI, DOMÁNY GYÖRGY, KOVÁCSNÉ BOZÓ ÉVA, BORZA ISTVÁN, FARKAS SÁNDOR
Format Patent
LanguageEnglish
Polish
Published 30.04.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a compound of formula (I): wherein: V and U are hydrogen, halogen, C1-C4 alkylamino, or together form a group that contains one or more heteroatoms, and that taken together with one or more: (a) hydrogen atoms; (b) carbon atoms; (c) -CH- groups; (d) -CH2- groups; or (e) additional heteroatoms of the same or different type; or any combination thereof, form a 4-7 membered homocyclic or heterocyclic ring, wherein the homocyclic or heterocyclic ring may combine with the phenyl group to form a bicyclic ring, and wherein the homocyclic or heterocyclic ring or the bicyclic ring may contain one or more oxo, thioxo, amino, mercapto, trifluoromethyl, C1-C4 alkyl, -S or -SH groups; W: is -CO-, -CH2- or -CH2-(C1-C4 alkyl)-; X: is -CO-; Y: is -O-, C1-C4 alkylene, C1-C4 alkynylene, cycloalkylene, aminocarbonyl, -NH-, -N(C1-C4 alkyl)-, -C1-C4 alkylene-N(C1-C4 alkyl)-, -CH2O-, -CH(OH)- or -OCH2-; Z: is hydrogen, halogen, nitro, amino, C1-C4 alkyl, C1-C4 alkoxy, cyano, trifluoromethyl, hydroxyl or carboxyl; R1 and R2: are hydrogen, or together form a C1-C3 bridge; and n and m: independently are 0-3, wherein n and m cannot each be 0; or an optical antipode, racemate or pharmaceutically-acceptable salt thereof. The carboxylic acid amide derivatives of formula (I) are highly effective and selective antagonists of the NMDA receptor.
Bibliography:Application Number: PL20020367259